A Phase 1B, randomized, double blind, placebo controlled, multiple-dose escalation study of NSI-189 phosphate, a neurogenic compound, in depressed patients

Molecular Psychiatry

Volumn 21, Issue 10, 2016, Pages 1372-1380

  Fava, M ^a,b   Johe, K ^c   Ereshefsky, L ^d   Gertsik, L G ^e   English, B A ^d   Bilello, J A ^f   Thurmond, L M ^f   Johnstone, J ^g   Dickerson, B C ^a   Makris, N ^a   Hoeppner, B B ^a,b   Flynn, M ^a   Mischoulon, D ^a,b   Kinrys, G ^a,b   Freeman, M P ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c Neuralstem Inc   (United States)

^d PAREXEL INTERNATIONAL   (United States)

^e CALIFORNIA CLINICAL TRIALS   (United States)

^f Ridge Diagnostics   (United States)

^g Q Metrx Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOPYRIDINE; NSI 189; PLACEBO; UNCLASSIFIED DRUG; AMINOPYRIDINE DERIVATIVE; NSI-189; PHARMACOLOGICAL BIOMARKER; PIPERAZINE DERIVATIVE; SEROTONIN UPTAKE INHIBITOR;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; COGNITION; COGNITIVE AND PHYSICAL FUNCTIONING QUESTIONNAIRE; COHORT ANALYSIS; CONTROLLED STUDY; DEPRESSION ASSESSMENT; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; FOLLOW UP; HEADACHE; HEART PALPITATION; HUMAN; INSOMNIA; IRRITABILITY; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; NAUSEA; NIGHTMARE; PARESTHESIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOMETRY; QUESTIONNAIRE; RANDOMIZED CONTROLLED TRIAL; RASH; RESTLESSNESS; SIDE EFFECT; SKIN PAIN; SLEEP QUALITY; SOMNOLENCE; SYMPTOM OF DEPRESSION QUESTIONNAIRE; VIVID DREAM; XEROSTOMIA; BLOOD; CLINICAL TRIAL; DEPRESSION; DOSE RESPONSE; METABOLISM; MIDDLE AGED; PSYCHOLOGICAL RATING SCALE; TREATMENT OUTCOME;

ADULT; AMINOPYRIDINES; BIOMARKERS, PHARMACOLOGICAL; DEPRESSION; DEPRESSIVE DISORDER, MAJOR; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; PSYCHIATRIC STATUS RATING SCALES; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84949254581     PISSN: 13594184     EISSN: 14765578     Source Type: Journal    
DOI: 10.1038/mp.2015.178     Document Type: Article

References (24)

1. Fava M, Davidson KG. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 1996; 19: 179-200.
2. Fava M. Diagnosis and definition of treatment-resistant depression. Biol Psychiatry 2003; 53: 649-659.
3. Nierenberg AA, Ostacher MJ, Huffman JC, Ametrano RM, Fava M, Perlis RH. A brief review of antidepressant efficacy, effectiveness, indications, and usage for major depressive disorder. J Occup Environ Med 2008; 50: 428-436.
4. Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L et al. STAR∗D study team. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR∗D: implications for clinical practice. Am J Psychiatry 2006; 163: 28-40.
5. Chang T, Fava M. The future of psychopharmacology of depression. J Clin Psychiatry 2010; 71: 971-975.
6. Cassano P, Fava M. Tolerability issues during long-term treatment with antidepressants. Ann Clin Psychiatry 2004; 16: 15-25.
7. Malberg JEl, Schechter LE. Increasing hippocampal neurogenesis: a novel mechanism for antidepressant drugs. Curr Pharm Des 2005; 11: 145-155.
8. Pascual-Brazo J, Baekelandt V, Encinas JM1. Neurogenesis as a new target for the development of antidepressant drugs. Curr Pharm Des 2014; 20: 3763-3775.
9. Targum SD, Pollack MH, Fava M. Redefining affective disorders: relevance for drug development. CNS Neurosci Ther 2008; 14: 2-9.
10. Desseilles M, Janet Witte J, Chang TE, Iovieno N, Dording C, Ashih H et al. Massachusetts General Hospital SAFER criteria for clinical trials and research. Harv Rev Psychiatry 2013; 21: 1-6.
11. Montgomery SA, Asberg M. A new depression rating scale designed to be sensitive to change. Br J Psychiatry 1979; 134: 382-389.
12. Guy W. Clinical Global Impression (CGI) ECDEU Assessment manual for Psycho-pharmacology. U.S. Dept Health Education and Welfare: Rockville, MD, 1976.
13. Pedrelli P, Blais MA, Alpert JE, Shelton RC, Walker RS, Fava M. Reliability and validity of the Symptoms of Depression Questionnaire (SDQ). CNS Spectr 2014; 2: 1-12.
14. Fava M, Iosifescu DV, Pedrelli P, Baer L. Reliability and validity of the Massachusetts general hospital cognitive and physical functioning questionnaire. Psychother Psychosom 2009; 78: 91-97.
15. Fischl B, Salat DH, Busa E, Albert M, Dieterich M, Haselgrove C et al. Whole brain segmentation: automated labeling of neuroanatomical structures in the human brain. Neuron 2002; 33: 341-355.
16. Jovicich J, Czanner S, Han X, Salat D, van der Kouwe A, Quinn B et al. MRI-derived measurements of human subcortical, ventricular and intracranial brain volumes: Reliability effects of scan sessions, acquisition sequences, data analyses, scanner upgrade, scanner vendors and field strengths. Neuroimage 2009; 46: 177-192.
17. Cohen J. Statistical power analysis for the behavioral sciences. 2nd (edn). Lawrence Erlbaum Associates, Inc.: Hillsdale, NJ, 1988.
18. Borges S, Chen YF, Laughren TP, Temple R, Patel HD, David PA et al. Review of maintenance trials for major depressive disorder: a 25-year perspective from the US Food and Drug Administration. J Clin Psychiatry 2014; 75: 205-214.
19. Femenía T, Gómez-Galán M, Lindskog M, Magara S. Dysfunctional hippocampal activity affects emotion and cognition in mood disorders. Brain Res 2012; 1476: 58-70.
20. Davidson RJ, Pizzagalli D, Nitschke JB, Putnam K. Depression: perspectives from affective neuroscience. Ann Rev Psychol 2002; 53: 545-574.
21. Fava M, Mischoulon D, Iosifescu D, Witte J, Pencina M, Flynn M et al. A double-blind, placebo-controlled study of aripiprazole adjunctive to antidepressant therapy among depressed outpatients with inadequate response to prior anti-depressant therapy (ADAPT-A Study). Psychother Psychosom 2012b; 81: 87-97.
22. Ratti E, Bettica P, Alexander R, Archer G, Carpenter D, Evoniuk G et al. Full central neurokinin-1 receptor blockade is required for efficacy in depression: evidence from orvepitant clinical studies. J Psychopharmacol 2013; 27: 424-434.
23. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K et al. Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010; 167: 748-751.
24. Fava M, Targum SD, Nierenberg AA, Bleicher LS, Carter TA, Wedel PC et al. An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery. J Psychiatr Res 2012a; 46: 1553-1563.